Nobel Prize Recipient, Louis Ignarro, on Scientific Committee of “Fondazione Internazionale Menarini”

FLORENCE, Italy, Oct. 24, 2019 /PRNewswire/ — His discoveries have changed the lives of millions of people. Thanks to his insight, he has won the world’s most prestigious scientific honour. Today, his valuable experience will contribute towards bolstering the mission of the “Fondazione Internazionale Menarini” which welcomes the winner of the Nobel prize for Medicine, Louis Ignarro.

Born in Brooklyn (New York), the son of Italian immigrants, Ignarro discovered his love for chemistry at the age of 8 when he carried out his first experiments with a children’s game. This passion never faded and, after a brilliant academic career at the Columbia University in New York and long periods of research in other prestigious American universities, he joined the University of California, Los Angeles (UCLA). It was during this time that he was awarded the Nobel Prize for Medicine and Physiology “for his contribution in discovering the workings of the nitric acid molecule in the cardiovascular system.” It is to his studies that we owe the development of medicines commonly used in treating erectile dysfunction and hypertension. Ignarro is one of the founders of the Nitric Oxide Society and is currently Professor of Pharmacology in the Department of Molecular Medical Pharmacology at the UCLA School of Medicine.

Speaking from Los Angeles, Louis Ignarro, had this to say about this exciting collaboration with the Foundation: “Having taught in several American universities, I have always appreciated the work carried out by the Fondazione Internazionale Menarini: their educational activities at congresses and on the internet represent a unique scientific asset. Thanks to this collaboration, I shall continue to contribute to the scientific instruction of researchers, clinicians, students, and young people.”

“We are honoured to have Professor Ignarro join our Scientific Committee,” commented Lorenzo Melani, Chairman and Scientific Director of the Fondazione Internazionale Menarini. “With the help of his experience, we shall continue to further promote research and understanding in the fields of biology, pharmacology, medicine, economics, and human sciences, which represent the institutional aims of the Fondazione Internazionale Menarini.”

For further information on “Fondazione Internazionale Menarini” visit the website https://www.en.fondazione-menarini.it/.

Photo – https://healthtechnologynet.com/wp-content/uploads/2019/10/Louis_Ignarro.jpg
Logo – https://healthtechnologynet.com/wp-content/uploads/2019/10/Menarini_Logo.jpg

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/nobel-prize-recipient-louis-ignarro-on-scientific-committee-of-fondazione-internazionale-menarini-300945011.html

SOURCE Menarini I.F.R.

Staff

Recent Posts

Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2025

– Revenue of $1,021.8 Million Grows 0.9% -- -- Revenue Increases 1.0% on Constant Currency…

4 hours ago

MaryRuth’s Celebrates TikTok Shop Super Brand Day With Exclusive Offers and Viral Favorites

LOS ANGELES, Jan. 12, 2025 /PRNewswire/ -- MaryRuth's, the trusted leader in liquid vitamins and…

10 hours ago

Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million

Preliminary unaudited product revenue for the fourth quarter of 2024 is expected to be approximately…

13 hours ago

Lipozem: Introducing Lipozem as the Bizarre Turmeric Hack for Weight Loss Support

LAKELAND, Fla., Jan. 12, 2025 (GLOBE NEWSWIRE) -- Lipozem emerges in an era where weight…

13 hours ago

AI Wellness Launches SoCal Fire Relief Initiative to Support Families and First Responders in Southern California

LOS ANGELES, Jan. 11, 2025 /PRNewswire/ -- Demonstrating a commitment to both innovation and compassion,…

22 hours ago

Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced…

2 days ago